Home › Funds › Octagon Capital Advisors LP › BIOA
Octagon Capital Advisors LP position in BIOA
BIOAGE LABS INC · Health Care
Octagon Capital Advisors LP reported holding 1,300,000 shares of BIOA (BIOAGE LABS INC) in its Q3 2026 13F filing — a position valued at US$9.2M, representing 1.23% of its reported portfolio and ranking #17 among its reported holdings. Octagon Capital Advisors LP has disclosed BIOA holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Octagon Capital Advisors LP's BIOA position evolved
Octagon Capital Advisors LP first disclosed a stake in BIOA in Q4 2025 at 1,598,000 shares (US$21.1M). The position peaked in Q2 2026 at 1,748,000 shares, worth US$42.8M. Across 4 filings, Octagon Capital Advisors LP increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 1,300,000 shares valued at US$9.2M — a reduction of -448,000 shares quarter over quarter.. Notable position changes include a 26% trim in Q3 2026 (shares fell 26% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 1.60M | $21.14M | New |
| Q1 2026 | 1.75M | $30.57M | Add |
| Q2 2026 | 1.75M | $42.84M | Hold |
| Q3 2026 | 1.30M | $9.22M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BIOA and 13F data
BIOA (BIOAGE LABS INC) is a Health Care company. 47 other funds we track also report a position in BIOA — the largest reported positions include a16z Capital Management, L.L.C. (US$22.9M), Sofinnova Investments, Inc. (US$16.3M), Cormorant Asset Management, LP (US$15.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BIOA
- a16z Capital Management, L.L.C. 3.23M sh · $22.92M · Q3 2026
- Sofinnova Investments, Inc. 2.29M sh · $16.26M · Q3 2026
- Cormorant Asset Management, LP 2.24M sh · $15.89M · Q3 2026
- MPM BioImpact LLC 1.86M sh · $13.16M · Q3 2026
- Sands Capital Alternatives, LLC 786.35K sh · $5.58M · Q3 2026
- Pivotal bioVenture Partners Investment Advisor LLC 653.37K sh · $4.63M · Q3 2026
- Cosmic Management, LLC 501.83K sh · $3.56M · Q3 2026
- Yiheng Capital Management, L.P. 294.04K sh · $2.08M · Q3 2026
- Comprehensive Financial Management LLC 271.84K sh · $1.93M · Q3 2026
- Squadron Capital Management LLC 250.00K sh · $1.77M · Q3 2026
More on Octagon Capital Advisors LP
FAQ
How long has Octagon Capital Advisors LP held BIOA?
Octagon Capital Advisors LP has disclosed BIOA holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Octagon Capital Advisors LP's current position in BIOA?
As of Q3 2026, Octagon Capital Advisors LP holds 1.30M shares of BIOA (BIOAGE LABS INC), valued at $9.22M, representing 1.23% of its reported portfolio and ranking #17.
Has Octagon Capital Advisors LP been buying or selling BIOA?
In the latest 13F filing (Q3 2026), Octagon Capital Advisors LP reduced its position in BIOA. The position peaked in Q2 2026 at 1.75M shares.
Which other funds hold BIOA?
Other major institutional holders of BIOA include a16z Capital Management, L.L.C., Sofinnova Investments, Inc., Cormorant Asset Management, LP, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.